Novartis(NVS) - 2023 Q1 - Earnings Call Transcript

Andrew Baum Thank you. Please forgive the voice. I'm struggling with COVID. A question for Vas, I suspect you remember, historically, I've described the bases is suffering from [indiscernible] syndrome in always being the early adopter and taking unnecessary risk relative to peers. IÂ'm going to completely contradict myself. The early data from SET with RT CD19 in refractory autoimmune is remarkable. The biology is strong, patient access node patients is much easier in oncology. We understand that Bristol i ...